Clinical trials: NSCLC Stage II
Lung Cancer, Non-Small Cell
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00871403
- Testing
- pazopanib and pemetrexed, pemetrexed and cisplatin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of veliparib when given together with or without cisplatin and etoposide and to see how well they work in treating patients with extensive stage small cell…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT01642251
- Testing
- Cisplatin, Etoposide, Veliparib
- Where
- 428 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Trial of Poor Performance Status Patients (ToPPS)
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
- Trial name
- ToPPS (NCT00892710)
- Testing
- Pemetrexed, Bevacizumab, Carboplatin
- Where
- 27 sites in United States
- Volunteers
- 172 people
- Sponsor
- SCRI Development Innovations, LLC
Non Small Cell Lung Cancer, Metastatic NSCLC
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or refractory, metastatic NSCLC.
- Conditions
- Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT05617313
- Testing
- Pembrolizumab, GT103
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ryan Dackor
Carcinoma, Non-Small-Cell Lung
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.
- Trial name
- PePS2 (NCT02733159)
- Testing
- pembrolizumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Birmingham
Non-small Cell Lung Cancer
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor…
- Trial name
- NCT03940703
- Testing
- Tepotinib, Osimertinib
- Where
- 179 sites in United States, Belgium and 15 more
- Volunteers
- 140 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Carcinoma
Neoadjuvant Pembrolizumab
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA…
- Trial name
- TOP 1501 (NCT02818920)
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Neal Ready MD PhD
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with…
- Trial name
- STOMP (NCT03004183)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Non-small Cell Lung Cancer, Brain Cancer
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases in patients with Non-Small Cell Lung…
- Trial name
- NCT00871923
- Testing
- Tarceva (Erlotinib hydrochloride), Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung, Solid Tumor
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon 14 mutation); or as a treatment…
- Trial name
- NCT02920996
- Testing
- Merestinib
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. Participants received daily oral doses of 150 mg Tarceva.
- Trial name
- NCT01378962
- Testing
- erlotinib
- Where
- 10 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
This phase II trial studies how well nivolumab works when given alone and in combination with ipilimumab or chemotherapy in treating patients with previously untreated stage I-IIIA non-small cell lung cancer.
- Conditions
- Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03158129
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus…
- Trial name
- NCT06926673
- Testing
- Dostarlimab, Belrestotug., Nelistotug
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 62 people
- Sponsor
- GlaxoSmithKline
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation…
- Conditions
- Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02444741
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
The main purpose of this study is to learn how patients with Advanced Non-Small Cell Lung Cancer (NSCLC) respond to the study drug Dasatinib. The study drug, Dasatinib, has been approved by the U.S.
- Trial name
- NCT00858403
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
The purpose of this study is: To find out if the chemotherapy treatment using Pemetrexed (Alimta) and Oxaliplatin (Eloxatin) given together will kill the cancer cells in the patient's body and shrink the size of their tumor.
- Trial name
- NCT00612677
- Testing
- Oxaliplatin, Pemetrexed
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281827
- Testing
- carboplatin, gemcitabine hydrochloride, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Carcinoma
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.
- Trial name
- NCT00592007
- Testing
- Fulvestrant and Erlotinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Lyudmila Bazhenova, M.D.
Lung Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00843726
- Testing
- Arm 1 stereotactic body radiation therapy, Arm II stereotactic body radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Roswell Park Cancer Institute